Collegium Pharmaceutical (COLL) Depreciation & Amortization (CF) (2014 - 2026)

Collegium Pharmaceutical's Depreciation & Amortization (CF) history runs 13 years deep, the most recent figure standing at $463000.0 for Q1 2026.

• In Q1 2026, Depreciation & Amortization (CF) fell 57.56% year-over-year to $463000.0; the TTM figure through Mar 2026 stood at $3.6 million (down 11.81% YoY), while the FY2025 annual figure was $4.2 million, up 8.45% from the prior year.
• Depreciation & Amortization (CF) was $463000.0 for Q1 2026 at Collegium Pharmaceutical, down from $923000.0 in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $1.1 million in Q2 2025 to a low of $463000.0 in Q1 2026.
• Historically, Depreciation & Amortization (CF) has averaged $863588.2 across 5 years, with a median of $917000.0 in 2024.
• The sharpest annual moves came in 2022 and 2026: Depreciation & Amortization (CF) soared 94.58% in 2022, then slumped 57.56% in 2026.
• A 5-year view of Depreciation & Amortization (CF) shows it stood at $825000.0 in 2022, then climbed by 15.03% to $949000.0 in 2023, then rose by 9.69% to $1.0 million in 2024, then slipped by 11.34% to $923000.0 in 2025, then slumped by 49.84% to $463000.0 in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $463000.0 (Q1 2026), $923000.0 (Q4 2025), and $1.0 million (Q3 2025), per Business Quant data.